Other products

VAL-63NAFLD

NAFLD (non-alcoholic fatty liver disease) is defined as an accumulation of excess fat in the liver, in the form of triglycerides. It can be considered to be a risk condition for developing NASH (non-alcoholic steatohepatitis). NAFLD prevalence, which is rapidly rising in developed countries, is around 25% for the general population, but it reaches 50% in patients with dyslipidemia, 50% to 70% in diabetic patients and 90% in morbidly obese patients.

VAL-63 NAFLD was specially developed as a preventive solution for NASH. Its formula particularly benefits from the active ingredient TOTUM-63, which has been proven to reduce liver triglycerides by approximately 50% (preclinical data), and is also perfectly safe for clinical use.

Approximately 40% of patients with NAFLD will develop NASH, which has become one of the most common reasons for undergoing a liver transplant.

VAL-630

VAL-630 is a medical nutrition product (Food for Special Medical Purposes) to offer nutritional support to patients with NASH and suitable for patients with type 2 diabetes. This new generation of medical nutrition products includes a patented innovative active ingredient with clinically proven effects.

Lipidrive®

Obesity is a chronic disease with serious health consequences. It largely explains the prevalence of type 2 diabetes.

In response to this real "epidemic", VALBIOTIS developed Lipidrive®, a patented extract obtained from a plant mixture. Preclinical tests show a positive effect on weight regulation, with specific action on body fat mass.

Experiments conducted on human adipocytes confirm the effects observed at the preclinical stage. A Phase I/II clinical study is underway.

VAL-070

The aim of the product VAL-070 is to meet the various needs created by the problem of mild to moderate dyslipidemia by identifying a composition able to act simultaneously on several lipid dysfunctions (LDL cholesterol and blood triglycerides) and on insulin sensitivity. VAL-070 is currently undergoing clinical development, and a Phase I/II clinical trial was initiated on people with mild to moderate dyslipidemia.